Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986012 + platinum–etoposide in first-line extensive-stage small cell lung cancer
2024-511824-15-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Atigotatug in small cell lung cancer (SCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events, Number of participants with serious adverse events and 4 more. Started May 2024; status: completed.
02
Drugs
Atigotatug
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-511824-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511824-15-00.